A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
Phase: PHASE2
Conditions: Plaque Psoriasis
Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Protocol J5B-MC-FHAG Version 4.0
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate 
the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
NCT05896527
Approval Date: 01-Nov-2023